文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗特应性皮炎的前瞻性反射式共聚焦显微镜监测

Prospective reflectance confocal microscopy monitoring in dupilumab-treated atopic dermatitis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-09-23

在阿根廷布宜诺斯艾利斯的三级学术医院开展前瞻性真实世界队列研究,纳入37例≥6个月中重度特应性皮炎患者,在基线、第12周和第24周评估临床与反射式共聚焦显微镜(RCM)特征。第24周中位EASI从28降至2,76.2%达到EASI-75,但表皮结构紊乱、海绵水肿和血管扩张在EASI-75应答者中仍常见。

要点

  • 度普利尤单抗治疗24周临床改善显著,EASI-75应答率76.2%。
  • 部分RCM特征如棘层肥厚、角化过度在第24周消退。
  • 表皮结构紊乱、海绵水肿和血管扩张在EASI-75应答者中仍持续存在。

核心结论

  • 第24周仍可见RCM异常,尤其是表皮结构紊乱、海绵水肿和血管扩张,即使在EASI-75应答者中也是如此。
  • 度普利尤单抗的临床应答可能并不总是与完全微结构正常化一致,RCM可提供临床结局之外的补充信息。

研究设计与样本

  • 前瞻性真实世界队列研究,在阿根廷布宜诺斯艾利斯的三级学术医院开展。
  • 连续纳入37例≥6个月的中重度特应性皮炎患者,起始度普利尤单抗治疗,在基线、第12周和第24周评估。
  • 采用配对基线至第24周分析评估患者内临床变化和RCM特征转变,并用Fisher精确检验和线性回归模型探索基线RCM特征与第24周结局的关联。

主要发现

  • 37例患者中19例(51.4%)为儿童,25例(67.6%)为男性,基线中位EASI为28.0(IQR 19.0-33.0)。
  • 基线RCM显示全部患者存在表皮结构紊乱、海绵水肿和血管扩张,34/37(91.9%)存在真皮-表皮交界处炎症。
  • 配对分析中,中位EASI从28(IQR 18-32)降至2(IQR 1-6),中位个体改善22分,76.2%达到EASI-75。
  • 基线阳性的RCM特征在第24周部分消退,包括棘层肥厚(81.8%)、角化过度(72.7%)、角化不全(66.7%)和表皮炎症/外渗(64.7%)。
  • 表皮结构紊乱、海绵水肿和血管扩张在第24周仍频繁存在,包括在EASI-75应答者中。

临床怎么用

  • 度普利尤单抗治疗中重度特应性皮炎时,临床改善可能不伴随完全微结构正常化。
  • RCM可作为临床结局之外的补充监测工具,但需更大研究验证其指导长期治疗决策的价值。

局限性

  • 样本量较小(37例),仅21例有完整基线和第24周评估。
  • 需要更大规模研究来理解RCM信息是否有助于指导长期治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab provides substantial clinical benefit in moderate-to-severe atopic dermatitis, but whether clinical improvement is accompanied by microstructural resolution on reflectance confocal microscopy (RCM) remains unclear. OBJECTIVES: To describe baseline clinical and RCM findings, evaluate longitudinal clinical and microstructural changes and explore associations between baseline RCM features and week 24 outcomes. METHODS: We conducted a prospective real-world cohort study at a tertiary academic hospital in Buenos Aires, Argentina. Consecutive paediatric and adult patients aged ≥6 months with moderate-to-severe atopic dermatitis initiating dupilumab were assessed at baseline, week 12 and week 24. Clinician-reported outcomes, patient-reported outcomes and prespecified binary RCM features were summarized at each visit. Paired baseline-to-week 24 analyses assessed within-patient clinical changes and RCM feature transitions. Associations between baseline RCM findings and week 24 outcomes were explored using Fisher's exact tests and linear regression models. RESULTS: Thirty-seven patients were included; 19 (51.4%) were paediatric and 25 (67.6%) were male. Baseline disease burden was high, with median EASI 28.0 (IQR 19.0-33.0). Baseline RCM showed epidermal disorganization, spongiosis and dilated vessels in all patients, with dermo-epidermal junction inflammation in 34/37 (91.9%). In paired baseline-to-week 24 analyses, median EASI decreased from 28 (IQR 18-32) to 2 (IQR 1-6), with a median individual improvement of 22 points; EASI-75 was achieved by 76.2%. Several baseline-positive confocal features resolved by week 24, including acanthosis (81.8%), hyperkeratosis (72.7%), parakeratosis (66.7%) and epidermal inflammation/exocytosis (64.7%). However, epidermal disorganization, spongiosis and dilated vessels remained frequent, including among EASI-75 responders. CONCLUSIONS: Persistent RCM abnormalities, particularly epidermal disorganization, spongiosis and dilated vessels, were observed at week 24, even among EASI-75 responders. These findings suggest that clinical response to dupilumab may not always coincide with complete microstructural normalization and that RCM may provide complementary information beyond clinical outcomes. Atopic dermatitis, also called eczema, is a common long‐term inflammatory skin disease that causes itchy, dry and inflamed skin. In moderate‐to‐severe cases, it can affect sleep, daily activities and quality of life. This study was carried out in Buenos Aires, Argentina. We followed children and adults with moderate‐to‐severe atopic dermatitis who were starting dupilumab, an injectable treatment used to reduce inflammation in this disease. We wanted to understand not only whether the skin improved clinically, but also whether microscopic changes inside the skin improved during treatment. To do this, we used reflectance confocal microscopy, a painless imaging technique that allows doctors to examine the upper layers of the skin without taking a biopsy. Thirty‐seven patients were included, and 21 had complete baseline and week 24 assessments. By week 24, clinical improvement was substantial: disease severity scores decreased markedly, and about three out of four patients achieved at least 75% improvement. Several microscopic skin abnormalities also became less frequent. However, some microscopic findings, such as altered epidermal structure, spongiosis and dilated vessels, were still present in many patients at week 24, including some whose eczema had clearly improved. These results suggest that the skin may continue to show subtle microscopic abnormalities even when symptoms and visible lesions improve. Larger studies are needed to understand whether this information can help guide long‐term treatment decisions, such as continuing, reducing or stopping therapy.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Mac Donald L, Angles MV, Luna PC, et al. Prospective reflectance confocal microscopy monitoring in dupilumab-treated atopic dermatitis. J Eur Acad Dermatol Venereol. 2026. PMID: 42775803. doi:10.1111/jdv.70725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。